CGIM
VRTX icon

Capital Group Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Group Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Buy
21,388
+304
+1% +$135K 1.6% 16
2026
Q1 		$9.41M Buy
21,084
+219
+1% +$102K 1.61% 14
2025
Q4 		$9.46M Sell
20,865
-5,421
-21% -$2.34M 1.54% 12
2025
Q3 		$10.3M Sell
26,286
-1,213
-4% -$507K 1.73% 13
2025
Q2 		$12.2M Buy
27,499
+3,647
+15% +$1.68M 2.18% 7
2025
Q1 		$11.6M Buy
23,852
+271
+1% +$126K 2.36% 8
2024
Q4 		$9.5M Buy
23,581
+2,435
+12% +$1.13M 1.8% 10
2024
Q3 		$9.83M Sell
21,146
-227
-1% -$109K 1.98% 8
2024
Q2 		$10M Buy
21,373
+178
+0.8% +$77.3K 2.16% 7
2024
Q1 		$8.86M Buy
21,195
+3,264
+18% +$1.38M 1.59% 11
2023
Q4 		$7.3M Buy
17,931
+1,008
+6% +$372K 0.77% 40
2023
Q3 		$5.88M Buy
16,923
+112
+0.7% +$39.2K 0.38% 82
2023
Q2 		$5.92M Buy
16,811
+2,234
+15% +$753K 0.29% 82
2023
Q1 		$4.59M Sell
14,577
-2,080
-12% -$624K 0.25% 90
2022
Q4 		$4.81M Buy
+16,657
New +$5.08M 0.19% 95

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Group Investment Management's VRTX Position: Q2 2026 in Review

Capital Group Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q2 2026, buying an estimated $135K and bringing the position to 21,388 shares worth $10.6M. The position accounts for 1.6% of the portfolio, ranked #16.

Capital Group Investment Management first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $12.2M in Q2 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Capital Group Investment Management held 21,388 shares of Vertex Pharmaceuticals worth $10.6M as of Q2 2026.
  • Capital Group Investment Management bought 304 Vertex Pharmaceuticals shares in Q2 2026, an estimated $135K.
  • Vertex Pharmaceuticals made up 1.6% of Capital Group Investment Management's portfolio in Q2 2026, its #16 holding.
  • Capital Group Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Capital Group Investment Management's Vertex Pharmaceuticals position peaked at $12.2M in Q2 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital Group Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.